Putting the award page together from the records…
Putting the award page together from the records…
TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION.
Up for re-bid: ends 2027-11-30. Recompete brief → · 2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases ↗
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
4 subawards totaling $127.5K (0.8% of what was obligated), as Baruch S. Blumberg Institute reported them. Primes report subawards of $30,000 or more; smaller ones and unreported ones aren't here.
| Subcontractor | Amount | Subawards | Where | First | Last |
|---|---|---|---|---|---|
| Utah State University | $127.5K | 4 | UT | 2023-05-31 | 2023-09-30 |
| Date | To | Amount | For |
|---|---|---|---|
| 2023-08-31 | Utah State University | $65.1K | SUBAWARD FOR PROJECT |
| 2023-05-31 | Utah State University | $26.6K | SUBAWARD FOR PROJECT |
| 2023-09-30 | Utah State University | $21.3K | SUBAWARD FOR PROJECT |
| 2023-06-30 | Utah State University | $14.5K | SUBAWARD FOR PROJECT |
12 actions since 2022-11-15. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-07-24 | P00011 | Administrative change | $0 | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| 2026-05-14 | P00010 | Option exercised | $3.76M | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| 2026-01-28 | P00009 | Supplemental agreement (work within scope) | $0 | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| 2025-08-12 | P00008 | Change order | $0 | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| 2025-03-13 | P00007 | Administrative change | $0 | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| 2025-01-14 | P00006 | Administrative change | $0 | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| 2024-09-17 | P00005 | Option exercised | $4.98M | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| 2024-04-18 | P00004 | Option exercised | $2.00M | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| 2024-04-18 | P00003 | Administrative change | $0 | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| 2023-09-27 | P00002 | Administrative change | $0 | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| 2023-03-17 | P00001 | Administrative change | $0 | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| 2022-11-15 | 0 | $5.49M | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-20). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗